ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Generally, the expected toxicity of combining RT with ICIs is low, particularly for programmed death(-ligand) 1 inhibitors. For most combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended. The evidence-based safety statements developed during this comprehensive project provide practical guidance on combining RT with targeted cancer therapies and immunotherapy.
Authors
- Diogo Martins-Branco (ORCID: https://orcid.org/0000-0002-7214-4818)
- Bharti Devnani (ORCID: https://orcid.org/0000-0001-8465-0905)
- Evert S.M. van Aken (ORCID: https://orcid.org/0000-0003-2358-4435)
- Corrie A.M. Marijnen (ORCID: https://orcid.org/0000-0003-0189-5953)
- Maria Antonietta Gambacorta (ORCID: https://orcid.org/0000-0001-5455-8737)
- George E. Pentheroudakis (ORCID: https://orcid.org/0000-0002-6632-2462)
- Claus Michael Rödel (ORCID: https://orcid.org/0009-0006-1777-2359)
- Séan M. O’Cathail (ORCID: https://orcid.org/0000-0001-5574-9199)
- Mechthild Krause (ORCID: https://orcid.org/0000-0003-1776-9556)
- Karin Lindberg
- M C de Jong
- Claus Belka (ORCID: https://orcid.org/0000-0002-1287-7825)
- P Boot
- Joaquín Aguilar Barriuso
- Ajeet Kumar Gandhi (ORCID: https://orcid.org/0000-0001-5713-0963)
- Demetris Papamichael (ORCID: https://orcid.org/0000-0002-2643-5569)
- Florian Lordick (ORCID: https://orcid.org/0000-0001-8591-9339)
- Richard Cathomas (ORCID: https://orcid.org/0000-0002-9677-9885)
- Markus Hecht (ORCID: https://orcid.org/0000-0003-2082-216X)
- Umberto Ricardi (ORCID: https://orcid.org/0000-0003-4406-7621)
- Stefan Nowicki
- Kevin Joseph Harrington (ORCID: https://orcid.org/0000-0002-6014-348X)
- Arsela Prelaj (ORCID: https://orcid.org/0000-0002-3863-088X)
- Giuseppe Caracciolo Minniti (ORCID: https://orcid.org/0000-0003-1239-1603)
- Ursula Nestle
- Luís Castelo-Branco (ORCID: https://orcid.org/0000-0002-3967-530X)
- Ángela Lamarca (ORCID: https://orcid.org/0000-0001-9696-6122)
- Dirk De Ruysscher (ORCID: https://orcid.org/0000-0002-1214-3557)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Goethe University Frankfurt (DE)
- Karolinska University Hospital (SE)
- Institute of Cancer Research (GB)
- All India Institute of Medical Sciences Jodhpur (IN)
- Heidelberg University (DE)
- European Society for Medical Oncology (CH)
- Beatson West of Scotland Cancer Centre (GB)
- University Medical Center Freiburg (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Heidelberg (DE)
- Cork University Hospital (IE)
- Agostino Gemelli University Polyclinic (IT)
- The Netherlands Cancer Institute (NL)
- Istituto Neurologico Mediterraneo (IT)
- LMU Klinikum (DE)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Universitario 12 De Octubre (ES)
- Institute of Oncology Research (CH)
- Kliniken Maria Hilf (DE)
- Royal Marsden Hospital (GB)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Dr. Ram Manohar Lohia Institute of Medical Sciences (IN)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Bank of Cyprus Oncology Center (CY)
- Kantonsspital Graubünden (CH)
- Erasmus MC Cancer Institute (NL)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Frankfurt Cancer Institute (DE)
- University Hospital Carl Gustav Carus (DE)
- University of Turin (IT)
- Universidad Autónoma de Madrid (ES)
- Ludwig-Maximilians-Universität München (DE)
- Saarland University (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.annonc.2025.09.008
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 10.63